vs

Side-by-side financial comparison of FRANKLIN STREET PROPERTIES CORP (FSP) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Zymeworks Inc. is the larger business by last-quarter revenue ($27.6M vs $26.0M, roughly 1.1× FRANKLIN STREET PROPERTIES CORP). FRANKLIN STREET PROPERTIES CORP runs the higher net margin — -28.1% vs -71.0%, a 42.9% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs -8.2%). FRANKLIN STREET PROPERTIES CORP produced more free cash flow last quarter ($-12.7M vs $-31.8M).

Franklin Street Properties Corp is a Massachusetts-based real estate investment trust (REIT) in the United States. It primarily invests in, owns, and operates high-quality office properties across major U.S. metropolitan markets, serving corporate tenants across various industry segments, and delivers stable long-term returns via rental income and strategic asset management.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

FSP vs ZYME — Head-to-Head

Bigger by revenue
ZYME
ZYME
1.1× larger
ZYME
$27.6M
$26.0M
FSP
Growing faster (revenue YoY)
ZYME
ZYME
+80.8% gap
ZYME
72.6%
-8.2%
FSP
Higher net margin
FSP
FSP
42.9% more per $
FSP
-28.1%
-71.0%
ZYME
More free cash flow
FSP
FSP
$19.2M more FCF
FSP
$-12.7M
$-31.8M
ZYME

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FSP
FSP
ZYME
ZYME
Revenue
$26.0M
$27.6M
Net Profit
$-7.3M
$-19.6M
Gross Margin
59.4%
Operating Margin
-27.9%
-80.1%
Net Margin
-28.1%
-71.0%
Revenue YoY
-8.2%
72.6%
Net Profit YoY
14.1%
34.3%
EPS (diluted)
$-0.06
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FSP
FSP
ZYME
ZYME
Q4 25
$26.0M
Q3 25
$27.3M
$27.6M
Q2 25
$26.7M
$48.7M
Q1 25
$27.1M
$27.1M
Q4 24
$28.4M
$31.0M
Q3 24
$29.7M
$16.0M
Q2 24
$30.8M
$19.2M
Q1 24
$31.2M
$10.0M
Net Profit
FSP
FSP
ZYME
ZYME
Q4 25
$-7.3M
Q3 25
$-8.3M
$-19.6M
Q2 25
$-7.9M
$2.3M
Q1 25
$-21.4M
$-22.6M
Q4 24
$-8.5M
$-23.5M
Q3 24
$-15.6M
$-29.9M
Q2 24
$-21.0M
$-37.7M
Q1 24
$-7.6M
$-31.7M
Gross Margin
FSP
FSP
ZYME
ZYME
Q4 25
59.4%
Q3 25
60.9%
Q2 25
59.9%
Q1 25
62.8%
Q4 24
59.7%
Q3 24
61.0%
Q2 24
64.2%
Q1 24
64.7%
Operating Margin
FSP
FSP
ZYME
ZYME
Q4 25
-27.9%
Q3 25
-30.5%
-80.1%
Q2 25
-29.2%
-1.4%
Q1 25
-78.9%
-94.5%
Q4 24
-29.9%
-71.6%
Q3 24
-52.4%
-213.8%
Q2 24
-68.0%
-222.9%
Q1 24
-24.0%
-376.9%
Net Margin
FSP
FSP
ZYME
ZYME
Q4 25
-28.1%
Q3 25
-30.5%
-71.0%
Q2 25
-29.5%
4.8%
Q1 25
-79.1%
-83.5%
Q4 24
-30.0%
-75.8%
Q3 24
-52.6%
-186.6%
Q2 24
-68.2%
-195.8%
Q1 24
-24.2%
-315.6%
EPS (diluted)
FSP
FSP
ZYME
ZYME
Q4 25
$-0.06
Q3 25
$-0.08
$-0.26
Q2 25
$-0.08
$0.03
Q1 25
$-0.21
$-0.30
Q4 24
$-0.09
$-0.32
Q3 24
$-0.15
$-0.39
Q2 24
$-0.20
$-0.49
Q1 24
$-0.07
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FSP
FSP
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$30.6M
$64.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$607.0M
$320.1M
Total Assets
$892.9M
$397.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FSP
FSP
ZYME
ZYME
Q4 25
$30.6M
Q3 25
$31.4M
$64.8M
Q2 25
$29.4M
$98.3M
Q1 25
$30.2M
$76.2M
Q4 24
$41.1M
$66.1M
Q3 24
$40.9M
$122.4M
Q2 24
$30.2M
$71.0M
Q1 24
$34.2M
$114.8M
Stockholders' Equity
FSP
FSP
ZYME
ZYME
Q4 25
$607.0M
Q3 25
$615.3M
$320.1M
Q2 25
$624.7M
$334.5M
Q1 25
$633.4M
$325.0M
Q4 24
$655.9M
$338.8M
Q3 24
$665.4M
$367.0M
Q2 24
$682.1M
$406.2M
Q1 24
$703.9M
$438.0M
Total Assets
FSP
FSP
ZYME
ZYME
Q4 25
$892.9M
Q3 25
$901.0M
$397.3M
Q2 25
$903.2M
$408.4M
Q1 25
$916.4M
$425.5M
Q4 24
$946.9M
$463.1M
Q3 24
$981.5M
$487.2M
Q2 24
$1.0B
$515.6M
Q1 24
$1.0B
$553.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FSP
FSP
ZYME
ZYME
Operating Cash FlowLast quarter
$3.8M
$-31.4M
Free Cash FlowOCF − Capex
$-12.7M
$-31.8M
FCF MarginFCF / Revenue
-48.6%
-115.2%
Capex IntensityCapex / Revenue
63.0%
1.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-25.3M
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FSP
FSP
ZYME
ZYME
Q4 25
$3.8M
Q3 25
$8.3M
$-31.4M
Q2 25
$-2.9M
$12.1M
Q1 25
$-5.5M
$-3.4M
Q4 24
$9.0M
$-41.5M
Q3 24
$14.5M
$-5.9M
Q2 24
$-648.0K
$-25.0M
Q1 24
$-7.1M
$-37.7M
Free Cash Flow
FSP
FSP
ZYME
ZYME
Q4 25
$-12.7M
Q3 25
$3.0M
$-31.8M
Q2 25
$-5.7M
$11.6M
Q1 25
$-9.9M
$-3.4M
Q4 24
$-16.2M
$-41.8M
Q3 24
$8.6M
$-6.8M
Q2 24
$-5.1M
$-25.6M
Q1 24
$-15.8M
$-37.9M
FCF Margin
FSP
FSP
ZYME
ZYME
Q4 25
-48.6%
Q3 25
11.0%
-115.2%
Q2 25
-21.5%
23.7%
Q1 25
-36.7%
-12.6%
Q4 24
-57.2%
-134.8%
Q3 24
29.1%
-42.4%
Q2 24
-16.7%
-133.0%
Q1 24
-50.8%
-377.5%
Capex Intensity
FSP
FSP
ZYME
ZYME
Q4 25
63.0%
Q3 25
19.4%
1.5%
Q2 25
10.7%
1.1%
Q1 25
16.4%
0.1%
Q4 24
88.9%
1.0%
Q3 24
19.6%
5.6%
Q2 24
14.6%
3.1%
Q1 24
28.1%
1.8%
Cash Conversion
FSP
FSP
ZYME
ZYME
Q4 25
Q3 25
Q2 25
5.21×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons